Nutriflex Special Solution For Infusion
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Nutriflex special Solution for Infusion
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
|
Before Mixing |
After Mixing |
Before Mixing |
After Mixing | |||
|
Lower compartment 500 ml |
Upper compartment 500 ml |
1000 ml |
Lower compartment 750 ml |
Upper compartment 750 ml |
1500 ml | |
|
L-Isoleucine |
4.11 g |
4.11 g |
6.17 g |
6.17 g | ||
|
L-Leucine |
5.48 g |
5.48 g |
8.22 g |
8.22 g | ||
|
L-Lysine |
3.98 g |
3.98 g |
5.97 g |
5.97 g | ||
|
L-Methionine |
3.42 g |
3.42 g |
5.13 g |
5.13 g | ||
|
L-Phenyl-alanine |
6.15 g |
6.15 g |
9.23 g |
9.23 g | ||
|
L-Threonine |
3.18 g |
3.18 g |
4.77 g |
4.77 g | ||
|
L-Tryptophan |
1.00 g |
1.00 g |
1.50 g |
1.50 g | ||
|
L-Valine |
4.54 g |
4.54 g |
6.81 g |
6.81 g | ||
|
L-Arginine |
4.73 g |
4.73 g |
7.10 g |
7.10 g | ||
|
L-Histidine |
2.19 g |
2.19 g |
3.29 g |
3.29 g | ||
|
L-Alanine |
8.49 g |
8.49 g |
12.74 g |
12.74 g | ||
|
L-Aspartic Acid |
2.63 g |
2.63 g |
3.95 g |
3.95 g | ||
|
L-Glutamic Acid |
6.14 g |
6.14 g |
9.22 g |
9.22 g | ||
|
Glycine |
2.89 g |
2.89 g |
4.34 g |
4.34 g | ||
|
L-Proline |
5.95 g |
5.95 g |
8.93 g |
8.93 g | ||
|
L-Serine |
5.25 g |
5.25 g |
7.88 g |
7.88 g | ||
|
Total Amino Acids |
70.0 g |
70.0 g |
105.0 g |
105.0 g | ||
|
Anhydrous Glucose |
240.0 g |
240.0 g |
360.0 g |
360.0 g | ||
|
Citric Acid Monohydrate |
0.210 g |
0.210 g |
0.420 g |
0.315 g |
0.315 g |
0.630 g |
|
Na+ |
40.5 mmol |
40.5 mmol |
60.8 mmol |
60.8 mmol | ||
|
K+ |
25.7 mmol |
25.7 mmol |
38.6 mmol |
38.6 mmol | ||
|
Ca++ |
4.1 mmol |
4.1 mmol |
6.2 mmol |
6.2 mmol | ||
|
Mg++ |
5.0 mmol |
5.0 mmol |
7.5 mmol |
7.5 mmol | ||
|
C1- |
8.2 mmol |
41.3 mmol |
49.5 mmol |
12.3 mmol |
62.0 mmol |
74.3 mmol |
|
H2PO4- |
14.7 mmol |
14.7 mmol |
22.1 mmol |
22.1 mmol | ||
|
Acetate |
22.0 mmol |
22.0 mmol |
33.0 mmol |
33.0 mmol | ||
|
Nitrogen (N) |
10.0 g |
10.0 g |
15.0 g |
15.0 g | ||
|
kJ (kcal) |
4020 (960) |
1175 (280) |
5195 (1240) |
6030 (1440) |
1760 (420) |
7790 (1860) |
3. PHARMACEUTICAL FORM
Intravenous infusion solution for parenteral nutrition.
4.1 Therapeutic indications
Parenteral nutrition with Nutriflex Special is indicated when nutritional supplementation is required and enteral nutrition is inadequate or impossible. Such situations may occur following surgery, trauma or burns, or when gastrointestinal absorption of nutrients is impaired.
Nutriflex Special contains a balanced mixture of essential and non essential amino acids, together with electrolytes and glucose.
4.2 Posology and method of administration
Shock and major acid base or electrolyte imbalance should be corrected before parenteral nutrition is commenced. Monitoring of nutritional and electrolyte status should be performed and trace element and vitamin levels should be assessed, particularly in the critically ill or those patients receiving prolonged parenteral nutrition.
In order to provide an appropriate input of calories and to fully metabolise the amino acids it is recommended that Nutriflex Special be administered in conjunction with a 20% lipid emulsion, eg Lipofundin MCT 20%.
|
Volume of Nutriflex Special |
Volume of Lipid (20%) |
Nitrogen (g) |
Glucose (kcal) |
Total non Protein (kcal) |
|
1000 ml |
250 ml |
10 |
960 |
1460 |
|
1500 ml |
500 ml |
15 |
1440 |
2440 |
Supplementation with further electrolytes, trace elements and vitamins may be required.
The above Nutriflex Special with lipid regimes have an osmolarity of about 990 mOsml/l and are recommended to be administered by continuous infusion over 24 hours through a central vein. The rate of infusion should be controlled so as to avoid rapid administration of large volumes. 1000 ml should not be administered in less than six to eight hours.
Children: Not to be used in babies and infants up to the age of 24 months.
4.3. Contra-indications
Parenteral nutrition is contraindicated in the case of
• Acute shock
• Inborn errors of amino acid metabolism
• Severe uraemia when dialysis facilities are not available
• Irreversible hepatic failure
• Renal failure where facilities for dialysis do not exist.
• Babies and infants up to the age of 24 months because of their different nutritional requirements.
4.4 Special warnings and precautions for use
As with all large volume infusion fluids, Nutriflex Special should be administered with caution to patients with cardiac or renal dysfuntion. Care should be exercised in the administration of parenteral nutrition solutions containing amino acids to patients with altered amino acid metabolism, or with hepatic dysfunction.
As with other solutions containing glucose, administration of Nutriflex Special may lead to hyperglycaemia. Blood glucose levels should be monitored and the rate of infusion adjusted or insulin administered if hyperglycaemia occurs.
Fluid, electrolyte and acid-base balance should be monitored. Administration of amino-acid solutions may cause acute folate deficiency and supplementary folic acid should be administered. Vitamin B12 status should be monitored and supplementation given if necessary.
As with all parenteral solutions administered through a central venous catheter, strict aseptic precautions should be taken when Nutriflex Special is infused. Care should be taken to avoid complications of catheterisation including an air embolism and central venous thrombosis.
4.5 Interaction with other medicinal products and other forms of interaction
No interactions with other medicaments have been reported with Nutriflex Special.
4.6 Fertility, pregnancy and lactation
Animal reproduction studies have not been performed with Nutriflex Special. There are however, published reports of successful and safe administration of its components during pregnancy in the human.
Nevertheless, medicines should not be used in pregnancy especially in the first trimester unless the expected benefit is thought to outweigh any possible risk to the fetus.
Breast-feeding is not recommended if women need parenteral nutrition in that time. 4.7. Effects on ability to drive and use machines Not applicable.
4.8. Undesirable effects
Nausea may occasionally occur. If the recommended infusion rate is exceeded, vomiting, sweating and flushing may occur. Abnormal results of liver function tests and cholestasis have been reported in some patients receiving parenteral nutrition.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 Overdose
Gross overdosage during total parenteral nutrition may lead to complications such as acidosis, hyperosmolar coma, hyperammonaemia. If Nutriflex Special is administered at the recommended rates no such problems are to be anticipated.
5. Pharmacological Properties
5.1. Pharmacodynamic properties
Nutriflex special contains the eight essential amino acids accompanied by semi-essential and non-essential amino acids and essential electrolytes in the optimum proportions necessary in cases of catabolism. Nitrogen balance being directly dependent on the energy/nitrogen ratio, the glucose contained in Nutriflex provides an optimum level of kcal/g of nitrogen ratio for an adequate nutritional supply.
5.2. Pharmacokinetic properties
Not applicable.
5.3. Preclinical safety data
None stated.
6.1 List of excipients
Citric acid monohydrate Water for injections
6.2 Incompatibilities
No additive or other component should be added to the medicinal product unless compatibility has been proven in advance. See also section 6.6.
6.3 Shelf life
Unopened
18 months
After first opening the container
The product should be administered immediately after connecting to infusion set. Partially used containers must not be stored for later use.
After mixing of the contents
Ideally after mixing the two solutions, Nutriflex special should be administered immediately but it can in special circumstances be stored for up to 7 days at room temperature and up to 14 days if stored in a refrigerator (including administration time).
6.4 Special precautions for storage
Do not store above 25 °C.
Keep bag in the outer carton in order to protect from light.
6.5 Nature and contents of container
Flexible plastic bag made of a dual-layer film consisting of polyamide (external layer) and polypropylene (internal layer). The container is divided into two equally sized compartments separated by an internal peel seam, of either 500 ml or 750 ml. Opening the peel seam results in an aseptic mixing of the two solutions.
Each bag is packed in a protective plastic bag.
Nutriflex special is supplied in two-chamber plastic bags containing:
- 1000 ml (500 ml of amino acids solution + 500 ml of glucose solution)
- 1500 ml (750 ml of amino acids solution + 750 ml of glucose solution)
Pack sizes: 5 x 1000 ml, 5 x 1500 ml Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No special requirements are needed for disposal of container, overwrap and oxygen absorber.
The design of the dual chamber bag permits aseptic mixing of amino acids, glucose and optional fat in the lower chamber. The addition of further electrolytes is possible if required.
Immediately before use the internal peel seam between the two compartments must be opened allowing the respective contents to be aseptically mixed.
Remove the bag from its protective bag and proceed as follows:
- Open out the bag and lay on a solid surface
- Open the peel seam by using pressure with both hands
- Briefly mix the contents of the bag together
An additive port is provided for admixing of supplements to Nutriflex special.
Only mixtures of known compatibility should be prepared. Information on compatibility is available from the manufacturer.
When admixing other solutions or fat emulsions to Nutriflex special, aseptic precautions must be strictly observed. Fat emulsions can be easily admixed by means of a special transfer set.
After infusion, any remaining solution should never be stored for later use. Only completely clear solutions from undamaged containers are to be used.
7. MARKETING AUTHORISATION HOLDER
B.Braun Melsungen AG Carl-Braun-Strasse 1 D-34212 Melsungen Germany
8. MARKETING AUTHORISATION NUMBER(S)
PL 03551/0024
9. DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
18th September 1996
10 DATE OF REVISION OF THE TEXT
03/09/2014